The Fanconi anemia group C gene product modulates apoptotic responses to tumor necrosis factor-α and Fas ligand but does not suppress expression of receptors of the tumor necrosis factor receptor superfamily

Experimental Hematology

Volumn 27, Issue 1, 1999, Pages 1-8

  Koh, Paul S ^a,b   Hughes, Grant C ^a,b   Faulkner, Gregory R ^a,b   Keeble, Winifred W ^a,b   Bagby, Grover C ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Fanconi anemia; Interferon gamma; Tumor necrosis factor receptor superfamily

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; GENE PRODUCT; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; FANCONI ANEMIA; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CELL TRANSFORMATION;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; DNA-BINDING PROTEINS; FANCONI ANEMIA COMPLEMENTATION GROUP C PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FAS LIGAND PROTEIN; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEAR PROTEINS; PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

HUMAN HERPESVIRUS 4;

EID: 0033015745     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(98)00064-2     Document Type: Article

References (91)

1. Auerbach A.D., Allen R.G. Leukemia and preleukemia in Fanconi anemia patients. a review of the literature and report of the International Fanconi Anemia Registry Cancer Genet Cytogenet. 51:1991;1.
2. Butturini A., Gale R.P., Verlander P.C., Adler-Brecher B., Gillio A.P., Auerbach A.D. Hematologic abnormalities in Fanconi anemia. an International Fanconi Anemia Registry study Blood. 84:1994;1650.
3. D'Andrea A.D., Grompe M. Molecular biology of Fanconi anemia. implications for diagnosis and therapy Blood. 90:1997;1725.
4. Liu J.M., Buchwald M., Walsh C.E., Young N.S. Fanconi anemia and novel strategies for therapy. Blood. 84:1994;3995.
5. Auerbach A.D., Adler B., Chaganti R.S. Prenatal and postnatal diagnosis and carrier detection of Fanconi anemia by a cytogenetic method. Pediatrics. 67:1981;128.
6. Auerbach A.D., Rogatko A., Schroeder-Kurth T.M. International Fanconi Anemia Registry. relation of clinical symptoms to diepoxybutane sensitivity Blood. 73:1989;391.
7. Strathdee C.A., Duncan A.M.V., Buchwald M. Evidence for at least four Fanconi anaemia genes including FACC on chromosome 9. Nature Genet. 1:1992;196.
8. Joenje H., Lo Ten Foe J.R., Oostra A.B., van Berkel C.G.M., Rooimans M.A., Schroeder-Kurth T., Wegner R.-D., Gille J.J.P., Buchwald M., Arwert F. Classification of Fanconi anemia patients by complementation analysis. evidence for a fifth genetic subtype Blood. 86:1995;2156.
9. Joenje H., Oostra A.B., Wijker M., di Summa F.M., van Berkel C.G., Rooimans M.A., Ebell W., van Weel M., Pronk J.C., Buchwald M., Arwert F. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet. 61:1997;940.
10. Strathdee C.A., Gavish H., Shannon W.R., Buchwald M. Cloning of cDNAs for Fanconi's anemia by functional complementation. Nature. 356:1992;763.
11. Yamashita T., Barber D.L., Zhu Y., Wu N., D'Andrea A.D. The Fanconi anemia polypeptide FACC is localized to the cytoplasm. Proc Natl Acad Sci U S A. 91:1994;6712.
12. Youssoufian H. Cytoplasmic localization of FAC is essential for the correction of a prerepair defect in Fanconi anemia group C cells. J Clin Invest. 97:1996;2003.
13. Youssoufian H. Localization of Fanconi anemia C protein to the cytoplasm of mammalian cells. Proc Natl Acad Sci U S A. 91:1994;7975.
14. Tower P.A., Christianson T.A., Peters S.T., Ostroski M.L., Hoatlin M.E., Zigler A.J., Heinrich M.C., Rathbun R.K., Keeble W., Faulkner G.R., Bagby G.C. Expression of the Fanconi anemia group C gene in hematopoietic cells is not influenced by oxidative stress, cross-linking agents, radiation, heat, or mitotic inhibitory factors. Exp Hemat. 26:1998;19.
15. Kupfer G.M., Naf D., Suliman A., Pulsipher M., D'Andrea A.D. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nature Genet. 17:1997;487.
16. Hoatlin M.E., Christianson T.A., Keeble W.W., Hammond A.T., Zhi Y., Heinrich M.C., Tower P.A., Bagby G.C. The Fanconi anemia group C gene product is located in both the nucleus and cytoplasm of human cells. Blood. 91:1998;1418.
17. Walsh C.E., Grompe M., Vanin E., Buchwald M., Young N.S., Nienhuis A.W., Liu J.M. A functionally active retrovirus vector for gene therapy in Fanconi anemia group C. Blood. 84:1994;453.
18. Segal G.M., Magenis R.E., Brown M., Keeble W., Smith T.D., Heinrich M.C., Bagby G.C. Jr. Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells. J Clin Invest. 94:1994;846.
19. Walsh C.E., Nienhuis A.W., Samulski R.J., Brown M.G., Miller J.L., Young N.S., Liu J.M. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector [see comments]. J Clin Invest. 94:1994;1440.
20. Cumming R.C., Liu J.M., Youssoufian H., Buchwald M. Suppression of apoptosis in hematopoietic factor-dependent progenitor cell lines by expression of the FAC gene. Blood. 88:1996;4558.
21. Whitney M.A., Royle G., Low M.J., Kelly M.A., Axthelm M.K., Reifsteck C., Olson S., Braun R.E., Heinrich M.C., Rathbun R.K., Bagby G.C., Grompe M. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood. 88:1996;49.
22. Rathbun R.K., Faulkner G.R., Ostroski M.H., Christianson T.A., Hughes G., Jones G., Cahn R., Maziarz R., Royle G., Keeble W.et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood. 90:1997;974.
23. Zoumbos N.C., Gascon P., Djeu J.Y., Young N.S. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A. 82:1985;188.
24. Young N.S. Gamma interferon and aplastic anemia (letter). Blood. 70:1987;337.
25. Hinterberger W., Adolf G., Aichinger G., Dudczak R., Geissler K., Hocker P., Huber C., Kalhs P., Knapp W., Koller U.et al. Further evidence for lymphokine overproduction in severe aplastic anemia [see comments]. Blood. 72:1988;266.
26. Nakao S., Yamaguchi M., Shiobara S., Yokoi T., Miyawaki T., Taniguchi T., Matsuda T. Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood. 79:1992;2532.
27. Nistico A., Young N.S. gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med. 120:1994;463.
28. Maciejewski J., Selleri C., Anderson S., Young N.S. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 85:1995;3183.
29. Selleri C., Sato T., Anderson S., Young N.S., Maciejewski J.P. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 165:1995;538.
30. Selleri C., Maciejewski J.P., Sato T., Young N.S. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood. 87:1996;4149.
31. Dai C.H., Price J.O., Brunner T., Krantz S.B. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood. 91:1998;1235.
32. Nagata S. Apoptosis by death factor. Cell. 88:1997;355.
33. Chinnaiyan A.M., O'Rourke K., Yu G.L., Lyons R.H., Garg M., Duan D.R., Xing L., Gentz R., Ni J., Dixit V.M. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science. 274:1996;990.
34. Tartaglia L.A., Weber R.F., Figari I.S., Reynolds C., Palladino M.A. Jr., Goeddel D.V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A. 88:1991;9292.
35. Kitson J., Raven T., Jiang Y.P., Goeddel D.V., Giles K.M., Pun K.T., Grinham C.J., Brown R., Farrow S.N. A death-domain-containing receptor that mediates apoptosis. Nature. 384:1996;372.
36. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233.
37. Bothwell M. p75. a receptor after all Science. 272:1996;506.
38. Trauth B.C., Klas C., Peters A.M., Matzku S., Moller P., Falk W., Debatin K.M., Krammer P.H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301.
39. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 169:1989;1747.
40. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169.
41. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449.
42. Cleveland J.L., Ihle J.N. Contenders in FasL/TNF death signaling. Cell. 81:1995;479.
43. Ju S.T., Panka D.J., Cui H., Ettinger R., el-Khatib M., Sherr D.H., Stanger B.Z., Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation [see comments]. Nature. 373:1995;444.
44. Owen-Schaub L.B., Yonehara S., Crump W., Ld Grimm E.A. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 140:1992;197.
45. Itoh N., Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem. 268:1993;10932.
46. Tartaglia L.A., Ayres T.M., Wong G.H., Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 74:1993;845.
47. Hsu H., Shu H.B., Pan M.G., Goeddel D.V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 84:1996;299.
48. Chinnaiyan A.M., Tepper C.G., Seldin M.F., O'Rourke K., Kischkel F.C., Hellbardt S., Krammer P.H., Peter M.E., Dixit V.M. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem. 271:1996;4961.
49. Tartaglia L.A., Goeddel D.V., Reynolds C., Figari I.S., Weber R.F., Fendly B.M., Palladino M.A. Jr. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol. 151:1993;4637.
50. Zheng L., Fisher G., Miller R.E., Peschon J., Lynch D.H., Lenardo M.J. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 377:1995;348.
51. Smith C.A., Gruss H.J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G.R., Brannan C.I., Copeland N.G., Jenkins N.A.et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 73:1993;1349.
52. Lee S.Y., Park C.G., Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med. 183:1996;669.
53. Foy T.M., Aruffo A., Bajorath J., Buhlmann J.E., Noelle R.J. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol. 14:1996;591.
54. Rathmell J.C., Townsend S.E., Xu J.C., Flavell R.A., Goodnow C.C. Expansion or elimination of B cells in vivo. dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor Cell. 87:1996;319.
55. Duckett C.S., Thompson C.B. CD30-dependent degradation of TRAF2. implications for negative regulation of TRAF signaling and the control of cell survival Genes Dev. 11:1997;2810.
56. Weiss T., Grell M., Hessabi B., Bourteele S., Muller G., Scheurich P., Wajant H. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80. requirement of the TNF receptor-associated factor-2 binding site J Immunol. 158:1997;2398.
57. Haneline L.S., Broxmeyer H.E., Cooper S., Hangoc G., Carreau M., Buchwald M., Clapp D.W. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood. 91:1998;4092.
58. Broxmeyer H.E., Williams D.E., Lu L., Cooper S., Anderson S.L., Beyer G.S., Hoffman R., Rubin B.Y. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia. synergism of tumor necrosis factor and interferon-gamma J Immunol. 136:1986;4487.
59. Maciejewski J.P., Selleri C., Sato T., Cho H.J., Keefer L.K., Nathan C.F., Young N.S. Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest. 96:1995;1085.
60. Whitney M.A., Saito H., Jakobs P.M., Gibson R.A., Moses R.E., Grompe M. A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. Nat Genet. 4:1993;202.
61. Miller A.D., Rosman G.J. Improved retroviral vectors for gene transfer and expression. Biotechniques. 7:1989;980.
62. Kozak S.L., Kabat D. Ping-pong amplification of a retroviral vector achieves high-level gene expression. human growth hormone production J Virol. 64:1990;3500.
63. Segal G.M., Smith T.D., Heinrich M.C., Ey F.S., Bagby G.C. Jr. Specific repression of granulocyte-macrophage and granulocyte colony-stimulating factor gene expression in interleukin-1-stimulated endothelial cells with antisense oligodeoxynucleotides. Blood. 80:1992;609.
64. Schmid I., Krall W.J., Uittenbogaart C.H., Braun J., Giorgi J.V. Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry. 13:1992;204.
65. Aggarwal B.B., Eessalu T.E., Hass P.E. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature. 318:1985;665.
66. Michishita M., Yoshida Y., Uchino H., Nagata K. Induction of tumor necrosis factor-alpha and its receptors during differentiation in myeloid leukemic cells along the monocytic pathway. A possible regulatory mechanism for TNF-alpha production. J Biol Chem. 265:1990;8751.
67. Ruggiero V., Tavernier J., Fiers W., Baglioni C. Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J Immunol. 136:1986;2445.
68. Tsujimoto M., Yip Y.K., Vilcek J. Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J Immunol. 136:1986;2441.
69. Nagafuji K., Shibuya T., Harada M., Mizuno S., Takenaka K., Miyamoto T., Okamura T., Gondo H., Niho Y. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood. 86:1995;883.
70. Boldin M.P., Varfolomeev E.E., Pancer Z., Mett I.L., Camonis J.H., Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem. 270:1995;7795.
71. Chinnaiyan A.M., O'Rourke K., Tewari M., Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:1995;505.
72. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14:1995;5579.
73. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 81:1995;495.
74. Stanger B.Z., Leder P., Lee T.H., Kim E., Seed B. RIP. a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death Cell. 81:1995;513.
75. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 85:1996;803.
76. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J.D., Zhang M., Gentz R.et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817.
77. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 protease nomenclature (letter). Cell. 87:1996;171.
78. Martin D.A., Siegel R.M., Zheng L., Lenardo M.J. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACH alpha1) death signal [In Process Citation]. J Biol Chem. 273:1998;4345.
79. Muzio M., Stockwell B.R., Stennicke H.R., Salvesen G.S., Dixit V.M. An induced proximity model for caspase-8 activation. J Biol Chem. 273:1998;2926.
80. Los M., Van de Craen M., Penning L.C., Schenk H., Westendorp M., Baeuerle P.A., Droge W., Krammer P.H., Fiers W., Schulze-Osthoff K. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature. 375:1995;81.
81. Enari M., Hug H., Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature. 375:1995;78.
82. Enari M., Talanian R.V., Wong W.W., Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature. 380:1996;723.
83. Tewari M., Dixit V.M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem. 270:1995;3255.
84. Hsu H., Huang J., Shu H.B., Baichwal V., Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 4:1996;387.
85. Yuan J. Transducing signals of life and death. Curr Opin Cell Biol. 9:1997;247.
86. Rothe M., Wong S.C., Henzel W.J., Goeddel D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell. 78:1994;681.
87. Ishida T.K., Tojo T., Aoki T., Kobayashi N., Ohishi T., Watanabe T., Yamamoto T., Inoue J. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci U S A. 93:1996;9437.
88. Liu Z.G., Hsu H., Goeddel D.V., Karin M. Dissection of TNF receptor 1 effector functions. JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death Cell. 87:1996;565.
89. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death [see comments]. Science. 274:1996;782.
90. Wang C.Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis. potentiation by inhibition of NF-kappaB [see comments] Science. 274:1996;784.
91. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB [see comments]. Science. 274:1996;787.